Preparation method and application of anti-l1cam antibody drug conjugate
By conjugating anti-L1CAM single-chain antibodies with DNA/RNA hybrid molecules and DM1, antibody-drug conjugates (ADCs) were formed, enabling precise targeted therapy in retinoblastoma. This solved the problems of low delivery efficiency and drug resistance in existing ADCs for RB treatment, and provided a highly effective eye-preserving treatment option.
CN122103339APending Publication Date: 2026-05-29SHENZHEN EYE HOSPITAL
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHENZHEN EYE HOSPITAL
- Filing Date
- 2026-02-11
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
Existing antibody-drug conjugates (ADCs) suffer from low tumor delivery efficiency, off-target toxicity, and drug resistance issues in the treatment of retinoblastoma (RB), which limit their clinical application.
Method used
A single-chain antibody against L1CAM was developed and conjugated with a DNA/RNA hybrid chain molecule and the cytotoxin DM1. The antibody specifically recognizes the extracellular region of L1CAM via ScFv, is internalized into target cells, and degrades the RNA region under the action of RNase H, releasing DM1 and inhibiting RB proliferation.
Benefits of technology
It achieves precise targeted treatment for retinoblastoma, inhibits tumor proliferation and metastasis, reduces toxic side effects, and provides an eye-preserving treatment plan.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122103339A_ABST
Abstract
The application provides a preparation method and application of an anti-L1CAM antibody drug conjugate, the anti-L1CAM antibody drug conjugate comprising an anti-L1CAM single-chain antibody, a DNA / RNA hybrid chain molecule and a cytotoxin DM1; the anti-L1CAM single-chain antibody is covalently connected to one end of the DNA / RNA hybrid chain molecule; the cytotoxin DM1 is covalently connected to the other end of the DNA / RNA hybrid chain molecule; and the DNA / RNA hybrid chain molecule comprises an RNase H sensitive segment. The technical scheme of the application specifically couples the anti-L1CAM single-chain antibody and the DM1 through the DNA / RNA hybrid chain, so that the obtained antibody drug conjugate integrates targeting, intelligent release and high-efficiency killing, has the effect of inhibiting retinoblastoma proliferation, and can effectively inhibit retinoblastoma proliferation and metastasis.
Need to check novelty before this filing date? Find Prior Art